Profile of fatty acids of erythrocyte membranes, blood serum of patients with steatosis and steatohepatitis in fatty liver disease of various genesis DOI Creative Commons
М. В. Кручинина,

R. A. Bukarev,

М. В. Паруликова

et al.

Ateroscleroz, Journal Year: 2025, Volume and Issue: 21(1), P. 6 - 22

Published: March 29, 2025

The aim of the study is to investigate possibilities using fatty acids erythrocyte membranes and blood serum differentiate steatosis steatohepatitis in patients with liver disease (FLD) various origins. Material methods . included 84 men FLD origins (alcoholic, non-alcoholic, mixed, i.e. alcoholic + metabolic), average age 48.4 ± 13.9 years, fibrosis degree 0-1 (FibroScan® 502 Echosens, France). Using tests NashTest, AshTest as part FibroMax, ActiTest FibroTest (BioPredictive, France), 44 showed minimal necroinflammatory activity tissue (steatosis), 40 pronounced necro- inflammatory (considered steatohepatitis). composition membrane, was carried out gas chromatography/mass spectrometry – a system based on three Agilent 7000B quadrupoles (USA). Results Fatty membranes, significant for differentiation genesis, were established: levels docosatetraenoic C22:4n-6 (p = 0.0001), arachidic C20:0 0.034) significantly higher, content pentadecanoic C15:0 (p=0.0006), 7-palmitoleic C16:1;7 0.0093), myristic C14:0 0.025), eicosapentaenoic C20:5n-3 0.032), hexadecadienoic acid C16:2 n-6 0.042) lower than those steatosis. greatest potential distinguishing demonstrated by AUC 0.736 (95 % CI 0.63–0.843), sensitivity 68.3 %, specificity 75.9 %. created diagnostic panel combination membrane (C15:0, C14:0, C16:1;7) highest 76.5 low 67.1 Conclusions identified features profile should be considered promising biomarkers detection from point view further research this area.

Language: Английский

Metformin and the Liver: Unlocking the Full Therapeutic Potential DOI Creative Commons
Federica Perazza, Laura Leoni, Santo Colosimo

et al.

Metabolites, Journal Year: 2024, Volume and Issue: 14(4), P. 186 - 186

Published: March 25, 2024

Metformin is a highly effective medication for managing type 2 diabetes mellitus. Recent studies have shown that it has significant therapeutic benefits in various organ systems, particularly the liver. Although effects of metformin on metabolic dysfunction-associated steatotic liver disease and steatohepatitis are still being debated, positive cirrhosis anti-tumoral properties, which can help prevent development hepatocellular carcinoma. Furthermore, been proven to improve insulin resistance dyslipidaemia, commonly associated with diseases. While more needed fully determine safety effectiveness use diseases, results promising. Indeed, terrific potential extending its full properties beyond traditional diabetes.

Language: Английский

Citations

9
Identification of common ferroptosis-related genes in metabolic dysfunction-associated steatotic liver disease and atherosclerosis using the support vector machine-recursive feature elimination algorithm DOI
Hua Deng, Xiaodong Wang,

Zichen Shao

et al.

Minerva Biotechnology and Biomolecular Research, Journal Year: 2025, Volume and Issue: 37(1)

Published: March 1, 2025

Language: Английский

Citations

1
Efficacy and Safety of Fibroblast Growth Factor‐21 Analogs for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis: A Systematic Review and Meta‐Analysis DOI Creative Commons

Changhyeon Jeong,

Nayoung Han, Nakyung Jeon

et al.

Clinical Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 116(1), P. 72 - 81

Published: April 26, 2024

Fibroblast growth factor (FGF)-21 analogs are potential therapeutic candidates for metabolic dysfunction-associated steatohepatitis (MASH). This systematic review and meta-analysis aimed to assess the efficacy safety of FGF-21 analogs, efruxifermin, pegbelfermin, pegozafermin MASH treatment. A comprehensive randomized controlled trials from five major databases was conducted. Primary outcomes focused on liver histological improvement, while secondary encompassed reductions in fat content improvements biochemical parameters. Safety examined included treatment-emergent adverse events (TEAEs), treatment-related TEAEs, TEAEs leading discontinuation, serious TEAEs. Eight eligible studies involving 963 patients were this review. Compared with placebo group, analog-treated group exhibited significantly improved primary outcomes, specifically ≥1 stage improvement fibrosis no worsening (risk ratio [RR] = 1.83; 95% confidence interval [CI] 1.27-2.62) at least two-point non-alcoholic fatty disease activity score (RR 2.85; CI 2.06-3.95). Despite an increased risk 1.17; 1.08-1.27) 1.75; 1.40-2.19), acceptable profile. better achieving beneficial compared placebo, a tolerable pattern. These findings shed light provide valuable evidence their application as therapeutics.

Language: Английский

Citations

7
The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus DOI
Monika Bhardwaj, Papiya Mitra Mazumder

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: June 11, 2024

Language: Английский

Citations

7
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals DOI

K.F. Au,

Ming‐Hua Zheng, Wei‐Jei Lee

et al.

Current Obesity Reports, Journal Year: 2024, Volume and Issue: 13(4), P. 818 - 830

Published: Aug. 7, 2024

Language: Английский

Citations

5
Advances in research on metabolic dysfunction-associated steatotic liver disease DOI
Jiawang Wang, Zhongyu Wang, Yao Yu

et al.

Life Sciences, Journal Year: 2025, Volume and Issue: 362, P. 123362 - 123362

Published: Jan. 4, 2025

Language: Английский

Citations

0
Design, synthesis and biological evaluation of Alisol B derivatives for potential treatment of non-alcoholic steatohepatitis DOI

Nai-Rong Yu,

Suling Huang, Zhen‐Tao Deng

et al.

Bioorganic Chemistry, Journal Year: 2025, Volume and Issue: 155, P. 108132 - 108132

Published: Jan. 7, 2025

Language: Английский

Citations

0
Association Between Sociodemographic Variables, Healthy Habits, and Stress with Risk Scales for Liver Disease Associated with Metabolic Dysfunction DOI Creative Commons
Ángel Arturo López‐González, Emilio Martínez-Almoyna Rifá, Hernán Paublini

et al.

Life, Journal Year: 2025, Volume and Issue: 15(1), P. 116 - 116

Published: Jan. 16, 2025

Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common cause of chronic worldwide, with a multifactorial etiology. This study aims to evaluate associations between various sociodemographic variables, healthy habits, and stress risk scale values for MAFLD. A descriptive, cross-sectional was conducted on 16,708 Spanish workers assess how variables (age, gender, socioeconomic status), habits (smoking, Mediterranean diet adherence, physical activity), correlate from three MAFLD scales: index (FLI), hepatic steatosis (HSI), lipid accumulation product (LAP). All analyzed were associated scales. Among them, showing strongest (represented by odds ratio values) age activity. The profile an individual at higher elevated male, aged 50 or older, belonging lower levels (manual laborers), smoker, sedentary, low adherence diet, high scores.

Language: Английский

Citations

0
The Role of Solute Carrier Family Transporters in Hepatic Steatosis and Hepatic Fibrosis DOI Open Access
Chi Zhang,

X Yang,

Yi Xue

et al.

Journal of Clinical and Translational Hepatology, Journal Year: 2025, Volume and Issue: 000(000), P. 000 - 000

Published: Jan. 22, 2025

Solute carrier (SLC) family transporters are crucial transmembrane proteins responsible for transporting various molecules, including amino acids, electrolytes, fatty and nucleotides. To date, more than fifty SLC transporter subfamilies have been identified, many of which linked to the progression hepatic steatosis fibrosis. These conditions often caused by factors such as non-alcoholic liver disease steatohepatitis, major contributors global burden. The activity members regulates transport substrates across biological membranes, playing key roles in lipid synthesis metabolism, mitochondrial function, ferroptosis. processes, turn, influence function hepatocytes, stellate cells, macrophages, thereby contributing development Additionally, some involved drug transport, acting critical regulators drug-induced steatosis. Beyond substrate certain also exhibit additional functions. Given pivotal role fibrosis, this review aimed summarize molecular mechanisms through these conditions.

Language: Английский

Citations

0
Peripheral Evolution of Tanshinone IIA and Cryptotanshinone for Discovery of a Potent and Specific NLRP3 Inflammasome Inhibitor DOI
Wenqi Zhu,

Xiaodong Bao,

Yuyan Yang

et al.

Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 23, 2025

Natural products (NPs) continue to serve as an invaluable source in drug discovery, and peripheral evolution of NPs is a highly efficient strategy. Herein, we describe unified "methyl amide" Tanshinone IIA Cryptotanshinone for discovery NLRP3 inflammasome inhibitors. There were 54 compounds designed prepared, while the chemoinformatic analysis revealed that these evolved NP analogues occupy unique chemical space. Biological evaluation identified 5m inhibitor, could directly bind NACHT domain protein block interaction ASC, thus suppressing ASC oligomerization assembly. Molecular dynamic stimulations amide moiety played vital role binding mode. Moreover, exhibited therapeutical efficacy sepsis NASH mouse model. In conclusion, this protocol provides new vision NPs' novel inhibitor.

Language: Английский

Citations

0